The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. - Wikidata - awgldk - TriplyDB

The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

http://www.wikidata.org/entity/Q37412673

about

Vascular Effects of Dietary Advanced Glycation End Products Vascular and cardiac impairments in rats inhaling ozone and diesel exhaust particles Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands.The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature Aldo-keto reductases in the eye.Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging EphA2-receptor deficiency exacerbates myocardial infarction and reduces survival in hyperglycemic mice.Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo.Disulfide bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis.Transgenic expression of human S100A12 induces structural airway abnormalities and limited lung inflammation in a mouse model of allergic inflammation Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial Endoplasmic reticulum stress induces the expression of COX-2 through activation of eIF2α, p38-MAPK and NF-κB in advanced glycation end products stimulated human chondrocytes.Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture Role of advanced glycation end products in cardiovascular disease.RAGE and tobacco smoke: insights into modeling chronic obstructive pulmonary disease.Advanced glycation end products acutely impair ca(2+) signaling in bovine aortic endothelial cells.sRAGE and risk of diabetes, cardiovascular disease, and death Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation.Immune mechanisms in atherosclerosis, especially in diabetes type 2 Effect of chronic hypoxia on RAGE and its soluble forms in lungs and plasma of mice.Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms Participation of the receptor for advanced glycation end products in efferocytosis.Glycation and biomarkers of vascular complications of diabetes.Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia.Molecular mechanisms of cardiomyocyte aging.An update on advanced glycation endproducts and atherosclerosis.Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction.Association of serum HMGB2 level with MACE at 1 mo of myocardial infarction: Aggravation of myocardial ischemic injury in rats by HMGB2 via ROS.Dietary Advanced Glycation End Products and Cardiometabolic Risk.Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs.The novel function of advanced glycation end products in regulation of MMP-9 production.Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction.Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.Inflammatory Biomarkers Predict Domain-Specific Cognitive Decline in Older Adults.Receptor for advanced glycation end-products and World Trade Center particulate induced lung function loss: a case-cohort study and murine model of acute particulate exposure

P2860

Q28081090-360F6479-EFE0-4F01-8845-470C5EB2EEDB Q28387006-6E8FAAF5-8509-45C3-A0CC-73CF371D0CC7 Q33556567-91BDC288-C70B-4786-89C6-39BFC7D80BD7 Q33822512-9C641323-C5A1-4C31-ADF5-33894D69E70D Q33984794-C8148C8E-8CAB-4D44-9970-1C16AA47330A Q34003967-1B24B9D0-9BBF-4C7C-BD93-08FF1EA56962 Q34062829-3D09A519-113F-4994-9CD3-43780673A617 Q34094369-F83D6D01-58EE-41CF-AE2F-C219942CAFC4 Q34100286-77D6DC72-84C2-48A7-A312-2A641868393D Q34517974-E24D7FB0-2E3A-4BE6-BD80-DFC937DB8032 Q34530243-4386F407-1642-4979-95B6-7979CE100D9A Q34531584-A35A2D22-2100-4466-A4AB-20A8D95374F7 Q34977648-F2BA388F-A274-4EA9-AE75-A54C866316F7 Q35180065-CE7AD89F-4C16-4865-8905-9D30B82C04DA Q35875201-201E8608-D3B1-4442-8EA9-DB31623C961E Q35881759-3AA727F0-9111-4D9E-A6AB-486A0E5E6C7B Q35929112-A947EC61-3102-4AA5-9FA8-DAC99C00E73C Q36193793-C5E385D9-4F37-41A8-9456-9F88BE7195F0 Q36671087-1DF43B5E-4A8F-4DD3-92A1-1BEA90252378 Q36867450-6A65D932-7F4C-4477-955E-DC1CDB7D24A6 Q37011769-8BB703FF-0CF9-4FC2-BD7A-F2BD20714088 Q37176678-2F676684-0777-4083-998B-B75E7D99E14A Q37261617-37E73B01-BE9E-42CD-AED5-C424ABE08C6A Q37404091-00B4D57E-2028-49DF-86F0-55DE057D1471 Q37636453-F178E93B-FFC6-4EE4-AE40-FA704A1A82B8 Q37638952-0EC08E17-13E3-42B2-BB0D-4D371C47A19D Q37806134-12E80FF8-6978-41DB-A3AC-802B83FFFD44 Q37850374-F5EBA3AD-9669-4CBA-B7B3-5123023219B9 Q37893685-E0E3E85E-D240-4FFC-88F0-8A2589A79F74 Q38001410-8BD54F30-E64F-495F-8667-09ABFB3299B6 Q38006722-F613F5F3-015E-4975-B0E4-08A01491F82C Q38430098-E82432B3-06E5-40B0-95ED-35F2795F16C0 Q38724566-94EA05F4-797B-4968-8D00-E423CFC20507 Q39427655-34759E9E-9DA1-43E1-BFE2-B845FF28AEA2 Q39436295-9F3C4BC7-E983-4BC0-B3E0-8D86915F5DFC Q39678954-C1C15594-7E5B-45A2-ADA3-56A9E1AFED4B Q39700115-F393A092-E4C3-4787-A63E-192FCE549138 Q40298930-93B8CDA0-A835-43D8-9FE7-0FDF6A3D6E0E Q40623318-7C88068A-2190-4A49-AF0A-11DA05D1E069 Q41571383-E708A53C-C930-46CE-B1EB-F9E272565ABA

P2860

The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

http://www.wikidata.org/entity/Q37412673

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

@en

The receptor for advanced glycation endproducts

@nl

type

label

The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

@en

The receptor for advanced glycation endproducts

@nl

prefLabel

The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

@en

The receptor for advanced glycation endproducts

@nl

P1433

Q37412673-D569BDCF-3F87-4B15-AFB1-71E06503144D

P1476

Q37412673-DE9DFDF6-2E32-4303-82DF-5405BD543F96

P2093

Q37412673-A5EE8E90-B5B1-4D3E-AEB6-BBA1558A45D3

Q37412673-AAC13673-5C4F-4C2C-8A63-808969A24C20

Q37412673-B4A47A52-78D9-4C05-AD8E-B4AA8D5DBF96

P2860

Q37412673-0439C65F-2869-4618-9A40-A2EB2ACB5328

Q37412673-07F07EF2-669D-4054-A647-4848E2010C03

Q37412673-0C7C4CA0-DDD4-41FC-A5BB-9D1472C29878

Q37412673-107F5C90-7154-4D45-A1AA-1CB2A2D6B231

Q37412673-14DF31D4-DAF2-4552-AA23-D9D58899C407

Q37412673-1E692D2C-FA48-4679-A636-3489D32751E5

Q37412673-20FFE909-A5E0-4112-885F-9CA7F4178D80

Q37412673-234563F3-7AA1-49AF-8C55-563D53CF0296

Q37412673-2353CD20-FEDF-4CB1-A416-16F0D6766E58

Q37412673-25A118EE-BF0C-4AE4-8C3A-A5C6D2BF995F

P304

Q37412673-0430CAE7-7233-443D-AE37-471CC809BADD

P31

Q37412673-48E68CA4-350E-40D6-A20E-BB70B8C5994D

P356

Q37412673-043803E1-5B1C-4C71-B1BF-6F6AE3E3EB64

P478

Q37412673-D938A73A-C429-4B3E-85A1-9605741E12ED

P577

Q37412673-7C4F7368-F8DF-4DDB-B38C-9798FDC09C0E

P698

Q37412673-DC3EC8FA-FA90-4240-BEF4-BCADB2C68AC8

P921

Q37412673-0B95E3F2-0667-4BFB-9A94-129E04446EED

P932

Q37412673-F6EF1711-0D69-4617-804F-D572977DF400

P356

S146239940900101X

P1433

Expert Reviews in Molecular Medicine

P1476

The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

@en

P2093

Ann Marie Schmidt

http://www.w3.org/2001/XMLSchema#string

Ravichandran Ramasamy

http://www.w3.org/2001/XMLSchema#string

Shi Fang Yan

http://www.w3.org/2001/XMLSchema#string

P2860

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains

Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products

N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression

Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice

A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys

P304

e9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S146239940900101X

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19278572

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

2670065

http://www.w3.org/2001/XMLSchema#string